MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

SpeedWeed

JUNE 14, 2021

State officials tasked with overseeing Ohio’s medical marijuana program approved last week the addition of three health conditions that qualify a patient to use cannabis medicinally. Spasticity is a medical condition characterized by prolonged muscle contraction and abnormal muscle tightness. List Of Conditions Reviewed Annually.

Conditions 40

Conditions Programs Therapy Patients 40

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions. Image by Pfüderi from Pixabay.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Leafwell

MAY 5, 2021

When it comes to caring for diseases and the most vulnerable among us, there are some clear areas where modern pharmaceutical medicine fails, and where medical marijuana succeeds.

Chronic Pain 52

Chronic Pain Epilepsy Law Pharmaceutical 52

MMJ Recs

FEBRUARY 18, 2024

This comprehensive article aims to explore the myriad health benefits of medical marijuana, delving into its therapeutic potential, impact on mental health, role in managing chronic conditions, and the holistic healing it offers, with a special focus on cannabinoids like CBD.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Many patients take MMJ for more reasons than one.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Of course, it’s wonderful to see the FDA approve this substance to help those suffering from this rare condition.

Access 98

Access Epilepsy Treatment Conditions 98

LifeCannMD

NOVEMBER 24, 2023

Our patients get a medical marijuana card for various reasons, primarily related to the potential medical benefits of using marijuana for various health conditions. The primary reason our patients choose to get their Medical Marijuana card is to manage symptoms and improve the quality of life for individuals with specific medical conditions.

Marijuana 52

Marijuana Chronic Pain Conditions Strains 52

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Epidiolex is also currently being evaluated for other epilepsy conditions, including tuberous sclerosis complex. Press Release.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

TheAnswerPage

MAY 20, 2022

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? GW Pharmaceuticals website. See the Answer.

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

TheAnswerPage

JANUARY 9, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JULY 24, 2019

Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition. It has been widely reported in the media that parents with children suffering from intractable epilepsy continue to experience difficulties in securing prescriptions for medical cannabis products containing THC.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Veriheal

JULY 26, 2023

The General Assembly finds that thousands of Georgians have serious medical conditions that can be improved by the medically approved use of cannabis and that the law should not stand between them and treatment necessary for life and health.” And Turnage has hinted that the regulation would be formalized soon.

Oil 98

Oil Patients Access THC 98

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! Another example, Age, weight, current health condition, sensitivities and even drug to drug interactions should be addressed.

Research and Development 108

Research and Development Indica Treatment Conditions 108

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 113

Law Epilepsy Programs Patients 113

TheAnswerPage

JULY 13, 2021

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Poland and cannabis.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

TheAnswerPage

AUGUST 19, 2021

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? GW Pharmaceuticals website. See the Answer.

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

Cannabis Law Report

APRIL 20, 2022

WROCLAW, Poland , April 19, 2022 /PRNewswire/ — Can4Med , a licensed wholesale specializing in medical products containing THC and cannabinoids has obtained Polish authorization to supply medical products and raw materials for cannabis pharmaceutical sales. About Can4Med.

Pharmaceutical 52

Pharmaceutical Patients Medicine Epilepsy 52

TheAnswerPage

JUNE 14, 2021

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? ” GW Pharmaceuticals website. See the Answer.

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52